What is the price target for AVIR stock?
9 analysts have analysed AVIR and the average price target is 6.12 USD. This implies a price increase of 2.51% is expected in the next year compared to the current price of 5.97.
ATEA PHARMACEUTICALS INC (AVIR) Forecast, Price Target & Analyst Ratings
NASDAQ:AVIR • US04683R1068
Current stock price
5.97 USD
+0.06 (+1.02%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ATEA PHARMACEUTICALS INC (AVIR).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 11, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.60
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$6.12
Upside
+ 2.51%
From current price of $5.97 to mean target of $6.12, Based on 9 analyst forecasts
Low
$6.06
Median
$6.12
High
$6.30
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
9 Wall Street analysts provided a forecast for the next 12 months for AVIR. The average price target is 6.12 USD. This implies a price increase of 2.51% is expected in the next year compared to the current price of 5.97.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.22%
AVIR was analyzed by 9 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about AVIR.
In the previous month the buy percentage consensus was at a similar level.
AVIR was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-09 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-04-11 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-08-13 | Morgan Stanley | Upgrade | Underweight -> Equal-Weight |
| 2023-08-10 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2023-03-16 | JP Morgan | Maintains | Neutral |
| 2023-01-27 | SVB Leerink | Maintains | Market Perform |
| 2023-01-24 | Morgan Stanley | Maintains | Underweight |
| 2022-08-15 | Morgan Stanley | Maintains | Underweight |
| 2022-03-02 | JP Morgan | Maintains | Neutral |
| 2022-03-01 | SVB Leerink | Maintains | Market Perform |
| 2022-02-16 | SVB Leerink | Maintains | Market Perform |
| 2022-01-06 | Morgan Stanley | Downgrade | Equal-Weight -> Underweight |
| 2021-11-18 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2021-10-20 | SVB Leerink | Maintains | Outperform |
| 2021-10-20 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2021-10-05 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2021-09-09 | SVB Leerink | Initiate | Outperform |
| 2021-08-18 | Morgan Stanley | Maintains | Overweight |
| 2021-06-03 | Morgan Stanley | Maintains | Overweight |
| 2021-04-06 | Morgan Stanley | Maintains | Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 11, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.60
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- -50.45%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-11.32%
EPS (3 Months)
-11.32%
Next Earnings Summary
AVIR is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -0.6 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 48.6M | 351.4M 623.05% | -100.00% | 31.402M | ||||||
| EBITDA YoY % growth | -14.6M -53.68% | 12M 182.19% | 231.9M 1,832.50% | -117.249M -147.82% | -141.259M -7.83% | -169.417M -10.03% | -142.676M -8.43% | -161.852M -13.44% | -96.182M 40.57% | |
| EBIT YoY % growth | -14.6M -53.68% | 12M 182.19% | 231.9M 1,832.50% | -124.805M -147.95% | -168.393M -7.91% | -197.841M -10.00% | -175.44M -32.91% | -172.38M 1.74% | -141.78M 17.75% | |
| Operating Margin | N/A | 24.69% | 65.99% | N/A | N/A | N/A | N/A | N/A | -451.50% | |
| EPS YoY % growth | N/A | N/A | 1.36 -4.99% | -1.46 -202.94% | -1.69 -17.14% | -2.00 -21.95% | -1.94 3.00% | -1.94 0.10% | -1.56 19.47% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.60 -50.45% | -0.53 -20.55% | -0.47 11.47% | -0.41 28.42% | -0.39 35.59% | -0.39 26.92% | -0.39 17.39% | -0.39 5.00% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -51M -34.90% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
14.82%
EBIT Next 5 Year
N/A
ATEA PHARMACEUTICALS INC / AVIR Forecast FAQ
When does ATEA PHARMACEUTICALS INC (AVIR) report earnings?
ATEA PHARMACEUTICALS INC (AVIR) will report earnings on 2026-05-11.
What are the consensus estimates for ATEA PHARMACEUTICALS INC (AVIR) next earnings?
The consensus EPS estimate for the next earnings of ATEA PHARMACEUTICALS INC (AVIR) is -0.6 USD and the consensus revenue estimate is 0 USD.